Literature DB >> 22983734

Criteria for the glucagon provocative test in the diagnosis of gastrinoma.

Chikashi Shibata1, Masayuki Kakyo, Makoto Kinouchi, Naoki Tanaka, Koh Miura, Takeshi Naitoh, Hitoshi Ogawa, Fuyuhiko Motoi, Shinichi Egawa, Tatsuya Ueno, Hiroo Naito, Michiaki Unno.   

Abstract

INTRODUCTION: The glucagon provocative test is useful for the diagnosis of gastrinoma. The aim of this study was to determine the criteria for the glucagon provocative test.
METHODS: This study reviewed 8 patients that underwent the glucagon provocative test preoperatively and in whom the diagnosis was confirmed as gastrinoma histologically. The glucagon provocative test was performed by administering glucagon (20 μg/kg) intravenously, followed by 20 μg/kg h for the next 30 min, and plasma gastrin levels were measured 3 and 1 min before and 3, 5, 7, 10, 15, 20, and 30 min after the administration of glucagon. This study evaluated the peak value of plasma gastrin and the time required to reach the peak.
RESULTS: Two of the 8 patients had multiple endocrine neoplasm type 1. The basal plasma gastrin levels ranged from 524 to 10,300 pg/ml. The time required to reach the peak was 3-10 min for all patients. The increase in the peak from the basal value was 235-8,920 pg/ml, and the percentage of increase was 38-337 %.
CONCLUSIONS: These results suggest that a diagnosis of gastrinoma should thus be made when plasma gastrin levels peak within 10 min after glucagon administration, with an increase of greater than 200 pg/ml and greater than 35 % of the basal value.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22983734     DOI: 10.1007/s00595-012-0334-2

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  17 in total

1.  Natural history and experience with diagnosis and treatment of the Zollinger-Ellison syndrome.

Authors:  J C Thompson; D D Reeder; H V Villar; H R Fender
Journal:  Surg Gynecol Obstet       Date:  1975-05

Review 2.  Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome.

Authors:  Masayuki Imamura; Izumi Komoto; Shuichi Ota
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

3.  The effect of glucagon on serum gastrin. I. Studies in normal subjects.

Authors:  J Hansky; C Soveny; M G Korman
Journal:  Gut       Date:  1973-06       Impact factor: 23.059

4.  Effect of glucagon on serum gastrin. II. Studies in pernicious anaemia and the Zollinger-Ellison syndrome.

Authors:  M G Korman; C Soveny; J Hansky
Journal:  Gut       Date:  1973-06       Impact factor: 23.059

5.  Zollinger-Ellison syndrome. Clinical presentation in 261 patients.

Authors:  P K Roy; D J Venzon; H Shojamanesh; A Abou-Saif; P Peghini; J L Doppman; F Gibril; R T Jensen
Journal:  Medicine (Baltimore)       Date:  2000-11       Impact factor: 1.889

6.  Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features.

Authors:  Marc J Berna; K Martin Hoffmann; Scott H Long; Jose Serrano; Fathia Gibril; Robert T Jensen
Journal:  Medicine (Baltimore)       Date:  2006-11       Impact factor: 1.889

7.  Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results.

Authors:  Scott H Long; Marc J Berna; Michelle Thill; Andrea Pace; Tapas K Pradhan; K Martin Hoffmann; Jose Serrano; Robert T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2007-08-21       Impact factor: 5.958

8.  The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome.

Authors:  Chikashi Shibata; Yuji Funayama; Kouhei Fukushima; Tatsuya Ueno; Atsushi Kohyama; Kennichi Satoh; Tooru Shimosegawa; Tetsuya Yamagiwa; Iwao Sasaki
Journal:  J Gastrointest Surg       Date:  2007-10-11       Impact factor: 3.452

Review 9.  Review article: Strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause.

Authors:  S V M Murugesan; A Varro; D M Pritchard
Journal:  Aliment Pharmacol Ther       Date:  2009-02-18       Impact factor: 8.171

10.  Clinical usefulness of the secretin provocation test.

Authors:  C B Lamers
Journal:  J Clin Gastroenterol       Date:  1981-09       Impact factor: 3.062

View more
  3 in total

1.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

Review 2.  Zollinger-Ellison syndrome: recent advances and controversies.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Curr Opin Gastroenterol       Date:  2013-11       Impact factor: 3.287

Review 3.  Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.

Authors:  Martine Bocchini; Fabio Nicolini; Stefano Severi; Alberto Bongiovanni; Toni Ibrahim; Giorgia Simonetti; Ilaria Grassi; Massimiliano Mazza
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.